Bavarian Nordic A/S (BVNKF) Research

Bavarian Nordic A/S is a biopharmaceutical company primarily focused on the development, production, and commercialization of life-saving vaccines. Its current portfolio of commercialized vaccines includes non-replicating options for smallpox and monkeypox (marketed as IMVAMUNE, IMVANEX, and JYNNEOS), a human rabies vaccine (Rabipur/RabAvert), an encephalitis vaccine targeting tick-borne varieties (Encepur), and an Ebola vaccine called MVABEA. Beyond its established products, Bavarian Nordic boasts a robust pipeline of investigational vaccines. These include MVA-BN (freeze-dried), which has concluded Phase III trials for smallpox treatment; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, having completed Phase II studies for SARS-CoV-2; and TAEK-VAC, undergoing Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The company also engages in strategic partnerships, holding a license and collaboration agreement with AdaptVac, as well as separate licensing agreements with the National Cancer Institute and the Public Health Service. Bavarian Nordic maintains a significant international presence, conducting operations across various countries such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, in addition to its broader global activities. Established in 1992, Bavarian Nordic A/S has its headquarters situated in Hellerup, Denmark.

Open Bavarian Nordic A/S (BVNKF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.